Viewing Study NCT02335918

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 5:03 AM
Ignite Modification Date: 2026-03-08 @ 1:06 AM
Study NCT ID: NCT02335918
Status: COMPLETED
Last Update Posted: 2019-12-09
First Post: 2014-12-18
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Sponsor: Celldex Therapeutics
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Squamous Cell Carcinoma of the Head and Neck (SCCHN) View
None Ovarian Carcinoma-Enrollment Completed View
None Colorectal Cancer (CRC)-Enrollment Completed View
None Renal Cell Carcinoma (RCC) (Phase ll Only) View
None Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Opdivo® View